Sex-related differences in cannabidiol's antinociceptive efficacy in a trigeminal neuralgia rodent model
- PMID: 40359363
- DOI: 10.1097/j.pain.0000000000003616
Sex-related differences in cannabidiol's antinociceptive efficacy in a trigeminal neuralgia rodent model
Abstract
Trigeminal neuralgia (TN) is a severe orofacial pain condition with sex-specific differences in pain responses. Standard treatments offer limited efficacy and significant side effects. We hypothesized that cannabidiol (CBD) alleviates TN-induced allodynia more effectively than carbamazepine in a sex- and dose-dependent manner through neuroimmune mechanisms, including modulation of glia, Fos protein expression, and oxidative stress in the ventrolateral periaqueductal gray (vlPAG) and spinal trigeminal nucleus caudalis (Sp5c). In an infraorbital nerve constriction model, mechanical allodynia was evaluated in male and female Wistar-Hannover rats. Our study demonstrates the potent antinociceptive effects of CBD in reducing mechanical allodynia in both male and female models of trigeminal neuralgia, without affecting locomotor activity, unlike carbamazepine. Although CBD's analgesic effects were consistent across sexes, carbamazepine showed sex-dependent efficacy. Cannabidiol's effects on Fos-B were region- and sex-dependent: it inhibited Fos-B in the Sp5c in both sexes but only in males in the vlPAG, suggesting sexually dimorphic activation of descendent pain circuits. Cannabidiol prevented superoxide oxidation in the vlPAG in both sexes, with effects on microglia and astrocytes at similar doses, suggesting that glial cells produce the oxidative stress inhibited by CBD. In the Sp5c, CBD modulated Fos-B, superoxide oxidation, microglia, and astrocytes in both sexes, indicating a possible lack of sexual dimorphism in this region. These results highlight CBD's efficacy in managing TN by modulating ascending and descending nociceptive pathways. Beyond its neuronal effects, CBD's analgesic actions in TN may also involve significant modulation of glial cell activity, underscoring the complexity of its therapeutic mechanisms.
Keywords: Cannabidiol; Periaqueductal gray; Spinal trigeminal nucleus caudalis; Trigeminal neuralgia.
Copyright © 2025 International Association for the Study of Pain.
References
-
- Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther 2011;90:844–51.
-
- Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, Mackie K, Marian C, Batkai S, Parolaro D, Fischer MJ, Reeh P, Kunos G, Kress M, Lutz B, Woolf CJ, Kuner R. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007;10:870–9.
-
- Artero-Morales M, González-Rodríguez S, Ferrer-Montiel A. TRP channels as potential targets for sex-related differences in migraine pain. Front Mol Biosci 2018;5:73.
-
- Atalay Ekiner S, Gęgotek A, Skrzydlewska E. The molecular activity of cannabidiol in the regulation of Nrf2 system interacting with NF-κB pathway under oxidative stress. Redox Biol 2022;57:102489.
-
- Bai X, Zhang X, Zhou Q. Effect of testosterone on TRPV1 expression in a model of orofacial myositis pain in the rat. J Mol Neurosci 2018;64:93–101.
MeSH terms
Substances
Grants and funding
- 2017/24304â€"0/Fundação de Amparo à Pesquisa do Estado de São Paulo
- 88887.635599/2021â€"00/Coordenação de Aperfeiçoamento de Pessoal de NÃ-vel Superior
- 420086/2023-4/Conselho Nacional de Desenvolvimento CientÃ-fico e TecnolÃ3gico
- 2023/16182-2/Fundação de Amparo à Pesquisa do Estado de São Paulo
- 420086/2023-4/Conselho Nacional de Desenvolvimento CientÃ-fico e Tecnolà 3 gico
LinkOut - more resources
Miscellaneous